News

MultiCell has scheduled a meeting with the Medicines and Healthcare Products Regulatory Agency to present its clinical development plan for MCT-125. Additionally, the company will request permission to

“This safety data is very encouraging and supports the potential for Cintredekin Besudotox delivered via Convection-Enhanced Delivery as a safe treatment option for patients with malignant glioma at

The research described pooled results from two phase III trials evaluating the safety and efficacy of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin in non-small

The agreement could be lucrative for Hospira as an increasing number of patents for biopharmaceuticals are expiring, opening up huge market opportunities for biosimilars manufacturers. Erythropoietin has sales

The study is evaluating the safety and efficacy of MEM 1003 for the treatment of acute mania in bipolar disorder. “We are particularly pleased by enrollment in this

This phase III trial was designed to assess the efficacy and safety of Silenor in elderly patients with primary sleep maintenance insomnia. Silenor demonstrated a statistically significant improvement

The two companies have agreed to develop small molecule anti-cancer drugs and Chi-Med can draw from its portfolio of over 10,000 natural substances to help manufacture the products.

Actelion will commence a cash tender offer of $13.50 per CoTherix share. The transaction is expected to conclude early in the first quarter of 2007. CoTherix currently markets

In these studies, Cera dosed every two weeks achieved as effective a response rate for correcting renal anemia as currently approved, more frequently-dosed agents, including Amgen’s Aransep. Amgen